司美格鲁肽登顶药王!诺和诺德、默沙东一季报揭晓战略分野

医药经济报
07 May

具体来看,诺和诺德的糖尿病业务产品销售额为550.44亿丹麦克朗,约合77.61亿美元,同比增长8%,这得益于旗下GLP-1产品和胰岛素销售额的增长。值得一提的是,诺和诺德的明星药物司美格鲁肽总共创造了557.76亿丹麦克朗(约合78.64亿美元)的营收,同比增长32%,约占总营收的71%,正式超过默沙东K药72.05亿美元的销售额,登顶全球“药王”。Wegovy销售额暴增83%以胰岛素研发起家的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10